Disease-related haplotype | No. of cases^{a} | Relative risk^{b} | ||||
---|---|---|---|---|---|---|

Analysis | 1.0 | 1.5 | 2.0 | 3.0 | ||

None^{c} | 200 | PENHAPLO | 0.052 | |||

500 | PENHAPLO | 0.058 | ||||

1000 | PENHAPLO | 0.058 | ||||

Major | 200 | PENHAPLO | — | 0.122 | 0.379 | — |

Method 4 | — | 0.113 | 0.298 | — | ||

500 | PENHAPLO | — | 0.292 | 0.836 | — | |

Method 4 | — | 0.230 | 0.734 | — | ||

1000 | PENHAPLO | — | 0.562 | 0.994 | — | |

Method 4 | — | 0.467 | 0.981 | — | ||

Minor | 200 | PENHAPLO | — | — | 0.246 | 0.828 |

Method 4 | — | — | 0.212 | 0.712 | ||

500 | PENHAPLO | — | — | 0.702 | 0.999 | |

Method 4 | — | — | 0.580 | 0.995 | ||

1000 | PENHAPLO | — | — | 0.976 | 1.000 | |

Method 4 | — | — | 0.915 | 1.000 |

↵

*a*The number of controls was the same as the number of cases.↵

*b*The relative risk was defined as the ratio of the penetrance with two disease-related haplotypes to that without any disease-related haplotype. When the simulations of disease-related haplotype were major, the additive risk model was assumed; when they were minor, the dominant model was assumed. The odds ratios for the dominant model corresponded to 2.25 and 3.9.↵

*c*The null hypothesis.